Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : A.forall
Deal Size : Undisclosed
Deal Type : Acquisition
A.forall Expands US Generics Portfolio
Details : With the acquisition, A.forall considerably extends its marketed portfolio in the US, including Dihydroergotamine Mesylate, for the treatment of migraine and cluster headaches.
Product Name : Dihydroergotamine Mesylate-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 09, 2025
Lead Product(s) : Dihydroergotamine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : A.forall
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Indigo Carmine
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ureteral Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2024
Lead Product(s) : Indigo Carmine
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indigo Carmine
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ureteral Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2023
Lead Product(s) : Indigo Carmine
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Indigo Carmine
Therapeutic Area : Urology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
Details : Indigotindisulfonate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ureteral Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Indigo Carmine
Therapeutic Area : Urology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Calyptus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Provepharm acquired global rights of the Cetrorelix acetate from Calyptus and will take on all development activities and ultimately commercial distribution upon approval.
Product Name : Cetrorelix Acetate-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 22, 2022
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Calyptus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved FDF
Recipient : American Regent
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches a New Vial Presentation
Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.
Product Name : ProvayBlue
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Recipient : American Regent
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate Disodium is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ureteral Injuries.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 14, 2020
Lead Product(s) : Phenylephrine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Recipient : Carilion Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Methylene Blue as a Third-line Vasopressor in Septic Shock
Details : Phenylephrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 13, 2019
Lead Product(s) : Phenylephrine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Recipient : Carilion Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MEthylene Blue In Patients With Acquired Methemoglobinemia
Details : Methylene Blue is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Methemoglobinemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2018
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
